Endoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn’s Disease  Guillaume Bouguen, Barrett G. Levesque, Suresh Pola, Elisabeth Evans, William J. Sandborn  Clinical Gastroenterology and Hepatology  Volume 12, Issue 6, Pages 978-985 (June 2014) DOI: 10.1016/j.cgh.2013.11.005 Copyright © 2014 AGA Institute Terms and Conditions

Figure 1 Cumulative probability of achieving MH. Clinical Gastroenterology and Hepatology 2014 12, 978-985DOI: (10.1016/j.cgh.2013.11.005) Copyright © 2014 AGA Institute Terms and Conditions

Figure 2 Flow chart of adjustments in medical therapy according to endoscopic findings during the study period. Adjustments in medical therapy included introduction or switch of immunosuppressive drug; introduction, optimization, or switch within the class or out of the class of biologics; or both immunosuppressive and biologics changes. MH was defined as no ulcer in any examined segment of the digestive tract. Clinical Gastroenterology and Hepatology 2014 12, 978-985DOI: (10.1016/j.cgh.2013.11.005) Copyright © 2014 AGA Institute Terms and Conditions

Figure 3 Kaplan–Meier analysis of reaching MH according to factors identified by multivariate analysis: (A) timeframe between endoscopic procedures shorter than 26 weeks; (B) adjustments in medical therapy were made according to the finding of ulcers at subsequent endoscopic procedures until MH occurred. Clinical Gastroenterology and Hepatology 2014 12, 978-985DOI: (10.1016/j.cgh.2013.11.005) Copyright © 2014 AGA Institute Terms and Conditions